This morning before the Tandem Investor Day began the company announced they were raising sales guidance from $140 to $148 million to $150 to $158 million. Naturally shares, which were already up almost 2000% over the past year, powered ahead.
Before we get into the gist of what happened at the investor event it’s appropriate to take a moment and look at how far Tandem has come. Keep in mind this is a company that was on the brink of bankruptcy, had a market cap below $30 million and seemed headed for the insulin pump graveyard.
But let’s . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.